External Advisory Committee Update
Summer 2023
Dr. Andrew G. Campbell, New Committee Member
Dr. Andrew G. Campbell joined the External Advisory Committee in February and brings a wealth of knowledge and experience to our program. Currently a principal investigator of two National Institutes of Health grants, and a previous recipient of four NSF awards, Dr. Campbell received several awards, from teaching excellence and faculty governance to AIDS research. Campbell, a Professor of Medical Science, completed a six-year term as the 15th Dean of Brown University’s Graduate School in 2022. He chose to return to teaching and performing research in the Department of Molecular Microbiology and Immunology of the Division of Biology and Medicine. Dr. Campbell’s expertise includes RNases H, novel nucleic acid metabolic functions associated with the enzymes, and their placement in the replicative life cycle of the pathogenic protozoan Trypanosoma brucei. He is the founding PI & Program Director, and current Co-Director of Brown University’s NIH-funded T32 graduate IMSD program established to increase the number of Ph. Ph.D.-level trained underrepresented trainees in STEM. He also serves as Co-Director and Co-PI of Brown University’s Postbaccalaureate Program.
Fall 2022
Michael A. Lynes, New Committee Chairman
We are happy to announce that Dr. Michael A. Lynes was designated as our External
Advisory Committee’s (EAC) new Chairman in July 2022. Dr. Lynes is a Professor of Molecular and Cell Biology, at the University of Connecticut’s main Storrs campus. Dr. Lynes is a Senior Fellow of the Cell Stress Society International and was selected as a Fulbright Scholar in 2021-2022. He has served as head of his department for the past decade.
Dr. Lynes has an active research program that is focused on the role of biological stress in shaping the immune response and, as part of that work has developed a therapeutic monoclonal antibody that has been used for the treatment of several different forms of chronic inflammatory disease (Inflammatory Bowel Disease, Drug-induced liver injury, and Type 1 Diabetes) in preclinical models. He is also part of the leadership team for a consortium of universities studying Multisystem Inflammatory Syndrome in Children (MIS-C), an adverse outcome of COVID infection in children. Dr. Lynes replaces our former chair Dr. Steven Cohen who has capably served as EAC Chair since 2013 and was a member of that committee since RI-INBRE’s inception in 2001.
Michael J. Hanley and Stevin Zorn, New EAC Members with an Industry Focus
Dr. Michael J. Hanley joined Takeda in 2012 and is a 
Scientific Director in the Quantitative Clinical Pharmacology department in Cambridge, Massachusetts. Michael is also a Registered Pharmacist in the state of Rhode Island and the Commonwealth of Massachusetts. He has a Doctor of Philosophy degree in Pharmacology and Experimental Therapeutics (Tufts University ‘12), and a Doctor of Pharmacy degree (URI ’07). Dr. Hanley was a RI-INBRE supported undergraduate student and performed research during the academic year (’04) and as a Summer Undergraduate Research Fellow (SURF ’05-’06) at URI. Dr. Hanley brings over 15 years of experience to our EAC and RI-INBRE is pleased to have a former SURF student involved in our program that can relate his experience and provide insight on future development.
Dr. Stevin Zorn is the President, Chief Executive Officer, and Co-Founder of 
MindImmune Therapeutics Inc. Dr. Zorn received M.S. and Ph.D. degrees in Neurotoxicology and Neuropharmacology, respectively (University of Texas Graduate School of Biomedical Sciences), and a B.S. degree in Chemistry (Lafayette College, PA).
MindImmune has a public-private collaboration with URI’s George and Anne Ryan Institute for Neuroscience and created a nucleus for biology, pharmacology, and neuroscience collaboration in Rhode Island. RI-INBRE is fortunate to have not only an industry executive but a neuropharmacologist with extensive executive experience throughout the pharmaceutical value chain and over 30 years of drug discovery and drug development success across a broad range of neuro and psychiatric disorders.
Please see the RI-INBRE Team page for a complete list of our committees and their members.